This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.LS Goldman , M Genel , RJ Bezman , PJ Slanetz . Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. J Am Med Asoc 1998; 279: 1100–1107.
3.L Hechtman , B Greenfield . Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs 2003; 5: 787–794.
4.American Academy of Pediatrics SoA-DHD. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033–1044.
5.VL Vetter , J Elia , C Erickson , Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407–2423.
6.American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008; 29: 335.
8.S Berger , JD Kugler , JA Thomas , DZ Friedberg . Sudden cardiac death in children and adolescents: introduction and overview. Pediatr Clin North Am 2004; 51: 1201–1209.
9.D Corrado , C Basso , M Schiavon , G Thiene . Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339: 364–369.
10.DR Neuspiel , LH Kuller . Sudden and unexpected natural death in childhood and adolescence. J Am Med Assoc 1985; 254: 1321–1325.
12.C Wren . Sudden death in children and adolescents. Heart 2000; 83: 410–413.
13.MJ Silka , BG Hardy , VD Menashe , CD Morris . A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998; 32: 245–251.
14.K Sayal . Epidemiology of attention-deficit/hyperactivity disorder in the community. Br J Hosp Med (Lond) 2007; 68: 352–355.
15.HH Hovels-Gurich , K Konrad , D Skorzenski , Long-term neurodevelopmental outcome and exercise capacity after corrective surgery for tetralogy of Fallot or ventricular septal defect in infancy. Ann Thorac Surg 2006; 81: 958–966.
16.AJ Shillingford , MM Glanzman , RF Ittenbach , RR Clancy , JW Gaynor , G Wernovsky . Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 2008; 121: e759–e767.
17.AG Winterstein , T Gerhard , J Shuster , M Johnson , JM Zito , A Saidi . Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007; 120: e1494–e1501.
18.MS Gould , BT Walsh , JL Munfakh , Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166: 992–1001.
19.BM Kuehn . Stimulant use linked to sudden death in children without heart problems. J Am Med Assoc 2009; 302: 613–614.
20.H Schelleman , WB Bilker , BL Strom , Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127: 1102–1110.
22.TS Faber , M Zehender , H Just . Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf 1994; 11: 463–476.
23.MJ Labellarte , JE Crosson , MA Riddle . The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003; 42: 642–650.
25.JF Wernicke , D Faries , D Girod , Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729–740.
28.P Denchev , JR Kaltman , M Schoenbaum , B Vitiello . Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010; 121: 1329–1337.
29.Y Tanaka , M Yoshinaga , R Anan , Usefulness and cost effectiveness of cardiovascular screening of young adolescents. Med Sci Sports Exerc 2006; 38: 2–6.
30.D Corrado , C Basso , A Pavei , P Michieli , M Schiavon , G Thiene . Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. J Am Med Assoc 2006; 296: 1593–1601.
31.PA Ubel , ML DeKay , J Baron , DA Asch . Cost-effectiveness analysis in a setting of budget constraints – is it equitable? N Engl J Med 1996; 334: 1174–1177.
32.RL Findling , EJ Short , MJ Manos . Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40: 525–529.
33.JA Samuels , K Franco , F Wan , JM Sorof . Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21: 92–95.
35.H Gutgesell , D Atkins , R Barst , Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99: 979–982.
36.TJ Spencer , M Greenbaum , LD Ginsberg , WR Murphy . Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19: 501–510.
37.E Lurbe , R Cifkova , JK Cruickshank , Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009; 27: 1719–1742.